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OBJECTIVE—Polymorphisms in the human TCF7L2 gene are
associated with reduced insulin secretion and an increased risk
of type 2 diabetes. However, the mechanisms by which TCF7L2
affect insulin secretion are still unclear. We deﬁne the effects of
TCF7L2 expression level on mature -cell function and suggest a
potential mechanism for its actions.
RESEARCH DESIGN AND METHODS—TCF7L2 expression
in rodent islets and -cell lines was altered using RNAi or
adenoviral transduction. -Cell gene proﬁles were measured by
quantitative real-time PCR and the effects on intracellular signal-
ing and exocytosis by live cell imaging, electron microscopy, and
patch clamp electrophysiology.
RESULTS—Reducing TCF7L2 expression levels by RNAi de-
creased glucose- but not KCl-induced insulin secretion. The
glucose-induced increments in both ATP/ADP ratio and cytosolic
free Ca
2 concentration ([Ca
2]i) were increased compared with
controls. Overexpression of TCF7L2 exerted minor inhibitory
effects on glucose-regulated changes in [Ca
2]i and insulin re-
lease. Gene expression proﬁling in TCF7L2-silenced cells re-
vealed increased levels of mRNA encoding syntaxin 1A but
decreased Munc18–1 and ZnT8 mRNA. Whereas the number of
morphologically docked vesicles was unchanged by TCF7L2
suppression, secretory granule movement increased and capac-
itance changes decreased, indicative of defective vesicle fusion.
CONCLUSION—TCF7L2 is involved in maintaining expression
of -cell genes regulating secretory granule fusion. Defective
insulin exocytosis may thus underlie increased diabetes inci-
dence in carriers of the at-risk TCF7L2 alleles. Diabetes 58:
894–905, 2009
T
ype 2 diabetes is the most common metabolic
disease in industrialized societies (1). The dis-
ease has a complex etiology involving interplay
between environmental risk factors (obesogenic
diet, lack of exercise) and a susceptible genetic back-
ground (2). Although the hereditary nature of type 2
diabetes has been acknowledged for many years (3), only
recently have candidate gene studies (4–6) and whole
genome association approaches (7–10) identiﬁed polymor-
phisms in 12 speciﬁc gene loci that increase disease risk.
These, and an earlier candidate gene study (11), identiﬁed
single nucleotide polymorphisms (SNPs), including SNP
rs7903146, in the third intron of the gene encoding tran-
scription factor 7-like 2 (TCF7L2; also known as transcrip-
tion factor 4) as strongly associated with type 2 diabetes in
different ethnic backgrounds (9–13). rs7903146 has been
estimated to contribute to 10 to 25% of all cases of diabetes
in lean individuals (14).
TCF7L2 is a member of the T-cell–speciﬁc high-mobility
group box-containing family of transcription factors that,
on binding -catenin, transduces signals generated by Wnt
receptors at the cell surface to modify expression of
multiple genes, many of which are associated with the cell
cycle (15). Mutations in TCF7L2 are also implicated in
certain types of cancer (16).
Recent clinical studies have demonstrated that the
at-risk SNP is associated with maintained insulin sensitiv-
ity (HOMA-B) but defects in -cell function and insulin
release (17). Because the SNP is found in an intronic
region, a potential mechanism through which it may
confer an increased risk of diabetes is by altering TCF7L2
expression levels. A recent study by Lyssenko and col-
leagues (18) suggested that pancreatic islets from patients
with type 2 diabetes bearing the at-risk TT allele have
increased TCF7L2 RNA levels, indicating that excessive
TCF7L2 expression may be associated with the reported
insulin-secretory defects. Expression studies carried out
by Elbein and colleagues (19) on adipose tissue and
muscle showed that TCF7L2 expression was not altered by
genotype and did not correlate with insulin sensitivity or
BMI. TCF7L2 mRNA levels in subcutaneous white adipose
tissue from TT-bearing individuals were decreased com-
pared with those in control (CC-bearing) individuals
(20,21). At present, data on TCF7L2 expression levels in
individuals carrying the at-risk allele are inconclusive, and
given the possibility of alternate splicing, it remains to be
established how the level of active TCF7L2 is altered.
Homozygous tcf7l2 knockout mice die shortly after
birth with profound changes in gut development involving
failed conversion of the endoderm to epithelial progeni-
tors (22). Although detailed morphometric analyses have
yet to be reported, pancreatic development is grossly
normal in homozygous mutant mice (22). A recent study in
isolated human islets demonstrated that RNAi-mediated
depletion of TCF7L2 mRNA led to ablation of glucose-
stimulated insulin secretion and increased -cell apoptosis
(23). To date, the mechanisms through which functional
TCF7L2 modulates glucose sensing and insulin release in
pancreatic -cells are unknown.
We provide a detailed investigation of the effects of
altering TCF7L2 content on -cell function and on the
expression of genes pivotal to -cell glucose sensing. We
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894 DIABETES, VOL. 58, APRIL 2009show that silencing of TCF7L2 in primary mouse islets as
well as in clonal MIN6 and INS-1(832/13) cells decreases
both basal- and glucose-stimulated insulin secretion.
TCF7L2 silencing also abolished the stimulatory effects of
GLP-1 on secretion while having little impact on glucose-
induced changes in intracellular ATP or free Ca
2 concen-
trations. We also show that TCF7L2 controls the
expression of genes involved in insulin granule fusion at
the plasma membrane. These changes may underlie defec-
tive insulin secretion in -cells lacking TCF7L2.
RESEARCH DESIGN AND METHODS
All reagents were purchased from Sigma (Poole, U.K.) or GIBCO-BRL
(Paisley, U.K.) unless otherwise stated. Mouse monoclonal antibody for
TCF7L2 was purchased from Abnova (Taiwan).
Culture of MIN6 and INS-1(832/13) -cell lines. MIN6 -cells were used
between passages 19 and 30 and cultured as previously described (24).
INS-1(832/13) cells were cultured as described (25). Cells were transfected
with plasmids and siRNA using Lipofectamine 2000 (Invitrogen, Paisley, U.K.)
or TransIT-TKO (Mirus Bio Corporation, Madison, WI), respectively, accord-
ing to the manufacturer’s instructions.
Isolation and culture of mouse islets. Islets were isolated from female CD1
mice and cultured as described (26).
TCF7L2 silencing. siRNA against mouse and rat TCF7L2 (sense-AAGAAGC-
CCCTTAATGCATTCCTGTCTC, antisense-AATGCATTAAGGGGCTTCTTTC-
CTGTCTC) and control siRNA (sense-AACCCGCAATTTAGAAGCATT-
CCTGTCTC, antisense-AATGCTTCTAAATTGCGGGTTCCTGTCTC) were de-
signed according to criteria set out by Tuschl and associates (http://www.
rockefeller.edu/labheads/tuschl/sirna.html and references therein) and
synthesized using Ambion’s Silencer siRNA kit (Ambion, Austin, TX). Fluo-
rescein-labeled siRNA duplexes of these sequences were from Sigma Genosys.
Enhanced green ﬂuorescent protein (EGFP)-tagged shRNA, based on the
previously mentioned siRNA, was synthesized by annealing oligonucleotides
containing the sequences for scrambled or TCF7L2 shRNA into pcDNA6.2/
GW/mir-EGFP (Invitrogen).
Overexpression of TCF7L2 in rodent -cells. Human TCF7L2 cDNA
(OriGene Technologies) was cloned into pEGFP-N1. TCF7L2-EGFP adenovi-
rus was generated as previously described (http://www.coloncancer.org/
adeasy.htm). Cells were infected with control or TCF7L2-EGFP adenovirus at
100 MOI for 48 h before experiments.
Real-time PCR analysis. Primers for real-time PCR analysis were designed
using Primer Express 3.0 (Applied Biosystems, Foster City, CA) using mRNA
sequences for mouse and rat on the Ensembl database (http://www.ensembl.
org/). Sequence speciﬁcity for all primers was veriﬁed using BLAST (http://
www.ncbi.nlm.nih.gov/blast/). Real time-PCR was performed on an ABI-Prism
Fast 7500 device (Applied Biosystems) using powerSYBR reagent (Applied
Biosystems).
Insulin secretion. Mouse islets and clonal cell lines were cultured in the
presence of siRNA (1 nmol/l or 10 nmol/l, respectively) for 48 h before insulin
secretion assay in Krebs-Ringer Bicarbonate Buffer (KRB; 125 mmol/l NaCl,
3.5 mmol/l KCl, 1.5 mmol/l CaCl2, 0.5 mmol/l NaH2PO4, 0.5 mmol/l MgSO4,3
mmol/l glucose, 10 mmol/l HEPES, and 2 mmol/l NaHCO3, pH 7.4, and
equilibrated with O2/CO2 [95:5] and supplemented with 0.1% [wt/vol] BSA)
(26,27). Secreted insulin was measured by radioimmunoassay (LINCO/Milli-
pore, St. Charles, MO).
Intracellular [Ca
2] imaging. INS-1(832/13) cells or mouse islets were
transduced 48 h before assay. INS-1(832/13) cells (incubated overnight in
media containing 3 mmol/l glucose) or dispersed islets were incubated for 30
min in KRB containing 3 mmol/l glucose and 200 nmol/l FURA-RED AM
(Invitrogen). Cells were stimulated using the conditions indicated and excited
at 480/440 nm using an Olympus IX-81 microscope coupled to an F-view
camera and captured using CellR ˆ software (Olympus, Hertfordshire, U.K.)
with a 40 oil objective. Data were expressed as the ratio of the ﬂuorescence
emission at 440/480 nm. The AUC was calculated using OriginPro7.5 software
(OriginLab, Northampton, MA) and statistical tests by ANOVA using Graph-
Pad Prism 4.0 (GraphPad Software).
Dual-color total internal reﬂection ﬂuorescence (TIRF) microscopy.
Transfected MIN6 cells were imaged at 30°C in KRB with 3 mmol/l glucose
using a custom-built lens-type TIRF microscope based on an inverted stand
(Axiovert 200M; Carl Zeiss) and equipped with a 100/1.45 Apo lens (Carl
Zeiss). Cells were excited using DPSS lasers (473 nm, 80 mW [EGFP] and 555
nm, 25 mW [mCherry]; Crystalasers) Emitted light was separated using a
double dichroic (59022 bs) magniﬁed with an Optovar 1.6 (Carl Zeiss) and split
into two channels using an image splitter (DualView; Optical Insights, Santa
Fe, NM) with a dichroic cutoff at 585 nm (T585LP) and bandpass ﬁlters 595 to
670 nm (ET630-75) and 485 to 550 nm (ET517/65M). All ﬁlters were from
Chroma. Separate images of the two channels were taken on a CCD camera
(Cascade 512B; Roper Scientiﬁc, Trenton, NJ, or iXon
EM  DU-897; Andor
Technology, Belfast, U.K.).
Cells were selected based on green ﬂuorescence and morphology. Gran-
ules were detected automatically with an in-house algorithm written as a
MetaMorph journal. The image was subjected to morphological tophat,
H-Dome, and dilate operations before internal thresholding and counting of
objects. A threshold was set by the operator once for the entire dataset.
Granule dynamics. All granule tracks were selected for each time period
using an Image J software particle tracker. The movement of each granule
between frames was then analyzed according to the equation ([x2  x1] [2]
 [y2  y1] [2]) and converted to microns per second generating a range of
granule movement velocities. The results were expressed as the number of
movements occurring at each velocity. Two distinct subgroups of granules
were observed (ﬁxed and moving), and analysis of the percentage of granules
in each subgroup was determined by curve ﬁtting to two sites (Origin
Software).
Confocal microscopy. Paraformaldehyde (4% wt/vol) ﬁxed INS-1(832/13)
cells previously transfected with either pEGFP-N1 or TCF7L2-pEGFP-N1 were
imaged using a Zeiss Axiovert 200M microscope ﬁtted with a PlanApo 63
oil-immersion objective and a 1.5 optivar. Sample illumination at 345 and 492
nm and data acquisition were controlled with an Improvision/Nokigawa
spinning disc system running Volocity (Improvision, Coventry, U.K.) software.
Total adenine nucleotide measurements. ATP (28) and ADP (29) were
quantiﬁed as previously described.
Electron microscopy. Isolated islets were treated with siRNA and glucose as
for secretion assays described previously and then ﬁxed in formaldehyde-
glutaraldehyde for 30 min at 37°C and postﬁxed in 1.0% osmium tetroxide.
Samples were processed for embedding in epon. Serial ultrathin 80-nm
sections were poststained with saturated methanolic uranyl acetate and
Reynold’s lead citrate and observed with a transmission electron microscope
(Tecnai G2 Spirit–FEI Company) at an operating voltage of 120 kV. Images
were collected using TEM v3.1 software (FEI Company) at a magniﬁcation of
2,700 with a 2k  2k CCD camera (Eagle; FEI Company). Islets were
sectioned at 20 m and 40 m from the surface and four cells imaged per
section. All imaging was carried out blind to treatment condition.
Analysis of electron microscopy images. Morphologically docked granules
were deﬁned using criteria previously described (30). To control for variations
in cell size resulting from the plane of section, the length of plasma membrane
was measured and the data expressed as granules per micron. Total granule
content was deﬁned as the granule number per micron squared of cytosol.
Statistical analysis was by ANOVA with Bonferroni post hoc analysis.
Electrophysiology. Electrical capacitance (Cm) and Ca
2 current (ICa)
through the plasma membrane of -cells were recorded using a EPC9
patch-clamp ampliﬁer controlled by Pulse software (HEKA Elektronik, Lam-
brecht/Pfalz, Germany) in standard whole-cell conﬁguration. Single -cells
from dispersed mouse islets were transfected with ﬂuorescein-labeled siRNA
as described for Ca
2 imaging.
Cells were voltage-clamped at 70 mV, and exocytosis was elicited by
trains of 200, 500, or 2,500 ms depolarizations to 10 mV essentially as
previously described (31). Noise reduction (1-D quadratic Loess) and data
analysis were performed using IgorPro software (Wavemetrics, Lake Oswego,
OR).
Data are given as means  SE of three to six individual experiments.
Unless otherwise described, comparisons between means were performed
using Student’s t test with Microsoft Excel.
RESULTS
Impact of TCF7L2 silencing on regulated insulin
secretion. The presence of TCF7L2 mRNA and protein
was conﬁrmed in mouse islets, MIN6 (mouse) and INS-
1(832/13) (rat) clonal -cells (Fig. 1A–C, respectively)
consistent with the reported expression of this protein in
human islets (18,23). Endogenous TCF7L2 mRNA levels
did not change in response to changing glucose concen-
trations in MIN6 and INS-1(832/13) cells (Fig. 1B and C).
Of three siRNAs designed against TCF7L2, one provided
substantial knockdown (76  0.2%, n  3 versus scram-
bled siRNA-treated cells) in TCF7L2 immunoreactivity in
mouse islets (Fig. 1A) after 48 h of siRNA treatment and
near total ablation of TCF7L2 immunoreactivity in MIN6
(Fig. 1B) and INS-1(832/13) (Fig. 1C) -cells.
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FIG. 1. siRNA-mediated knockdown of TCF72 in mouse islets and clonal -cell lines leads to defective glucose-stimulated insulin secretion. Mouse
islets (A, top left), MIN6 (B, top left), and INS-1(832/13) (C, top left) -cells were transfected as described in RESEARCH DESIGN AND METHODS.
Immunoblot analysis was carried out using 50 g of protein extract. Anti-TCF7L2 antibody (Abnova, Taiwan) was used at 1:1,000 and revealed
by chemiluminescence after blotting with anti-mouse–horseradish peroxidase (HRP) conjugated antibody. Band intensity was quantiﬁed using
ImageJ software. Real-time PCR analysis of RNA extracts from mouse islets (A, bottom left), MIN6 (B, bottom left), and INS-1(832/13) (C, bottom
left) -cells revealed that siRNA treatment led to 75  3.57%, 71.0  0.7%, and 75.2  19.8% decrease, respectively, in TCF7L2 message levels.
Mouse islets (A, right), MIN6 (B, right), and INS-1(832/13) (C, right) -cells were treated with siRNA as described above prior to insulin
secretion assays as described in RESEARCH DESIGN AND METHODS. Released and total insulin were assayed using an insulin radioimmunoassay kit from
Linco. Data are means  SEM, n  3. A: , control siRNA; f, TCF7L2 siRNA. B: , 3.0 mmol/l glucose; o, 10 mmol/l glucose; f, 30 mmol/l glucose.
C: , 3.0 mmol/l glucose; o, 10 mmol/l glucose; f, 30 mmol/l glucose; z, 3.0 mmol/l glucose  KCl.
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effect on total islet insulin content (74.9  4.4 versus
69.7  3.2 ng/islet, n  3; 54 islets per condition), but
resulted in a decrease in both the basal (3 mmol/l) and
glucose stimulated (11 mmol/l) insulin release (Fig. 1A).
Similar changes were seen in two -cell lines (Fig. 1B and
FIG. 2. TCF7L2 knockdown in mouse pancreatic islets and INS-1(832/13) -cells does not alter glucose-stimulated changes in intracellular free [Ca
2]
but alters total cellular ATP and ADP levels. Mouse islets were treated and intracellular adenine nucleotide measured as described in RESEARCH DESIGN
AND METHODS (A). Dissociated mouse islet cells (B and C) and INS-1(832/13) -cells (D and E) were treated with 10 nmol/l ﬂuorescein-labeled siRNA
(B and C) or pEGFP-TCF7L2 shRNA (D and E) and incubated with FURA-Red (200 nmol/l; B–E) for [Ca
2]i measurement. Typical traces are shown (C
and D). Glucose-induced (3.0 versus 11 mmol/l) [Ca
2]i changes in individual glucose-responsive dissociated mouse islet cells in which TCF7L2 was
silenced (B) and the number of INS-1(832/13) cells within the cell population that responded to (20 mmol/l) glucose (E) are shown. Data are means 
SEM, n  3, unless otherwise stated in the RESEARCH DESIGN AND METHODS. AUC, area under the curve; FITC, ﬂuorescein isothiocyanate.
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FIG. 3. A: Overexpression of TCF7L2-EGFP has no effect on glucose-stimulated insulin secretion. Insulin secretion from mouse islets
overexpressing TCF7L2-EGFP was assessed as described in RESEARCH DESIGN AND METHODS. , 3.0 mmol/l glucose; f, 15 mmol/l glucose; p, 3.0 mmol/l
glucose  KCl. B: Overexpression and subcellular localization of TCF7L2-EGFP in INS-1(832/13) cells was assessed by confocal microscopy 48 h
after plasmid transfection. Scale bar  15 m. [Ca
2]i imaging was performed as described in RESEARCH DESIGN AND METHODS. C and E:
Representative traces of [Ca
2]i responses to glucose (3 versus 20 mmol/l) stimulation are shown for EGFP-N1 vector (C) and TCF7L2-EGFP (E).
The proportion of cells that displayed glucose– or GLP-1–induced [Ca
2]i changes are shown in D and F, respectively (, EGFP-N1; f,
TCF7L2-EGFP). Data are means  SEM, n  3. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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898 DIABETES, VOL. 58, APRIL 2009C) in concurrence with studies in human islets (23). By
contrast, insulin release stimulated by cell depolarization
with high concentrations of K
 (30–50 mmol/l) was unaf-
fected in islets (Fig. 1A) and INS-1(832/13) cells (Fig. 1C),
implying a defect in metabolic signaling in response to
elevated glucose (32) or a depletion of pool(s) of secretory
granules with relatively high Ca
2 sensitivity (33).
Whereas basal total cellular ATP and ADP levels were
lower in TCF7L2-silenced mouse islets, glucose-induced
changes in this ratio were augmented (0.46  0.10- and
0.73  0.24-fold respectively compared with control; Fig.
2A). Similarly, glucose-induced changes in cytosolic-free
calcium ion concentration ([Ca
2]i; Fig. 2B and C) were
augmented in mouse islets (Fig. 2B and C). Glucose-
induced changes in [Ca
2]i in INS-1(832/13) cells were not
affected by TCF7L2 depletion (Fig. 2D), although the
number of cells responding to elevated glucose was higher
(46  10.3% versus 71  2.9%, P 	 0.05). In mouse islets,
the stimulation of insulin secretion by GLP-1 at permissive
(8 mmol/l) glucose concentrations was abolished when
TCF7L2 was silenced (Fig. 1A).
Impact of TCF7L2 overexpression on insulin secretion.
Given the reportedly higher levels of TCF7L2 mRNA in
islets from carriers of the at-risk (T) allele (18), we
examined the effect of overexpressing EGFP-tagged hu-
man TCF7L2 (TCF7L2-EGFP) in mouse islets or INS-1(832/
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FIG. 4. Silencing and overexpression of TCF7L2 in mouse pancreatic islets lead to changes in expression of islet genes. Mouse pancreatic islets
were cultured continuously in the presence of control (), TCF7L2 siRNA (o), or control and TCF7L2-EGFP (f) virus for 48 h. Total RNA was
isolated as described in RESEARCH DESIGN AND METHODS, and islet gene expression was assessed by real-time PCR. Genes are grouped according to
function: transcription factors (A), exocytosis (B), hormones, glucose sensing, and membrane transport (C), and signaling (D). Data are means 
SEM, n  3. *P < 0.05 versus control.
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FIG. 5. Syntaxin 1A and Munc18-1 are regulated by TCF7L2. Mouse pancreatic islets were treated with TCF7L2 siRNA as described in RESEARCH
DESIGN AND METHODS, and protein content was assessed by immunoblot analysis. A: Typical blots are shown. B: Quantiﬁcation of immunoblots from
three separate sets of samples using ImageJ is shown (, control siRNA; f, TCF7L2 siRNA). TIRF microscopy of MIN6 cells treated with
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to the nucleoplasm (Fig. 3B). Increases in TCF7L2 protein
level (approximately fourfold; Fig. 3A) in mouse islets did
not affect glucose-stimulated (15 versus 3 mmol/l) insulin
secretion (Fig. 3A). Likewise, overexpression of TCF7L2-
EGFP did not affect glucose-induced [Ca
2]i increases in
INS-1(832/13) cells (Fig. 3A and C). By contrast, the
proportion of INS-1(832/13) cells responding to high glu-
cose after transfection with TCF7L2-EGFP was lower
(31.8  3.7% versus 47.5  4.0%, P 	 0.05) than in cells
treated with control (EGFP-expressing) plasmid (Fig. 3D).
The increase in [Ca
2]i in response to GLP-1 of cells
overexpressing TCF7L2-EGFP was not different from that
of EGFP-transfected cells (Fig. 3E).
Impact of TCF7L2 expression levels on islet and
-cell gene expression. To explore the mechanisms
through which over- or underexpression of TCF7L2 may
exert effects on insulin secretion, we examined the expres-
sion of genes that are involved in various aspects of -cell
function. Systematic real-time PCR analysis of scrambled
or TCF7L2 siRNA-treated mouse islets was used to quan-
titate the expression of 32 genes implicated in the control
of -cell function or survival (supplemental Table 1, avail-
able in an online appendix at http://diabetes.diabetes
journals.org/cgi/content/full/db08-1187/DC1, and Fig. 4).
Of these, 25 displayed consistent changes in islets de-
pleted of, or overexpressing, TCF7L2 (Fig. 4; n  6
separate mouse islet preparations). Depletion of TCF7L2
caused a small (
20%) but signiﬁcant decrease in prepro-
insulin mRNA levels, whereas overexpression of this fac-
tor approximately doubled preproinsulin mRNA levels.
Conversely, preproglucagon mRNA was increased on
TCF7L2 deletion, although overexpression of TCF7L2-
EGFP exerted no clear effect on preproglucagon mRNA
level. Neither TCF7L2 silencing nor overexpression ex-
erted detectable effects on the mRNA level of the glucose
transporter or on glucokinase, two key proteins involved
in the control of glucose metabolism.
Islets treated with TCF7L2 siRNA also displayed de-
creased expression of preproinsulin but increased levels
of mRNA encoding the TCF regulator -catenin and the
transcription factor FoxO-1, previously shown to inﬂuence
the expression of pancreatic homeobox-1 (33). Similarly,
mRNAs encoding the SNARE protein syntaxin 1A and the
cell cyclin-dependent kinase cdk5 were increased by
TCF7L2 silencing. In none of these cases did TCF7L2
overexpression cause a reciprocal decrease in mRNA
levels. Expression of the sec family member Munc18–1
(34), the granule zinc transporter ZnT8/Slc30a8 (35) (also
recently associated with increased risk of type 2 diabetes
[9]), the peptidylprolyl cis/trans isomerise pin1 (36), and
the proliferation marker ki67 (23) were all decreased when
TCF7L2 was silenced. In the cases of Munc18-1 and ZnT8,
TCF7L2 overexpression led to reciprocal increases in the
coding mRNAs (Fig. 4), implicating the latter genes as
direct transcriptional targets of TCF7L2. Changes in
Munc18-1 and syntaxin 1A were also veriﬁed at the protein
level by Western (immuno-) blotting (Fig. 5A and B). There
was no change in the expression of the granule trafﬁcking
proteins myosin5a and Kif5b or the signaling molecule
PI3kinase-c2-.
It was recently reported that patients carrying the SNP
rs7903146 respond poorly to sulfonylurea treatment (37).
We therefore determined the effect of TCF7L2 silencing on
the expression of the ATP-sensitive K
 (KATP) channel.
Depleting TCF7L2 had no effect on the expression of either
the Kir 6.2 or SUR1 components in mouse islets (Fig. 4).
Effect of TCF7L2 on the subcellular distribution of
secretory granules. To explore the potential mecha-
nisms through which changes in the expression of genes
involved in granule dynamics and/or membrane fusion
may affect secretion, we used TIRF microscopy of neu-
ropeptide-labeled dense core granules (38). This approach
allowed the number of granules immediately beneath
(100–200 nm) the plasma membrane to be determined in
scrambled shRNA or anti-TCF7L2 shRNA-transfected
MIN6 cells. No differences in granule number beneath the
cell surface were observed (0.38  0.03 and 0.48  0.04
granules/m
2, P  0.05, for 43 and 55 cells, respectively).
There was an increase (41.8%, P 	 0.01) in the proportion
of granules moving after 6 to 8 min of glucose stimulation,
however, implying a defect in granule recruitment or
tethering (Fig. 5D–F). To further explore this possibility,
we used electron microscopy analysis of siRNA-trans-
fected islets to quantify tethered granules. There was no
signiﬁcant difference in granule number per micron mem-
brane between control and TCF7L2 siRNA-treated islets in
either the morphologically docked pool (0.26  0.02
versus 0.19  0.02, n  15–17 cells; Fig. 6) or the pool
within 200 nm of the plasma membrane (0.87  0.06 versus
0.78  0.05, n  15–17 cells).
Effect of TCF7L2 on granule fusion and Ca
2 currents.
These results implicated defects in the machinery of
vesicle fusion in cells depleted of TCF7L2. We hypothe-
sized that the differences may be observed in response to
“mild” stimulation with glucose, resulting in oscillatory
[Ca
2]i increases, but may be lost when [Ca
2]i is raised
for a lengthy period during K
 depolarization (see Fig. 1A).
To test this hypothesis, the effect of TCF7L2 silencing on
granule fusion was measured using a whole-cell patch-
clamp. Stimulation protocols were used to provide oscil-
latory increases in [Ca
2]i as observed during stimulation
with glucose. Exocytosis was triggered by trains of mem-
brane depolarizations of different duration: 20  0.25 s,
10  0.50 s, or 10  2.5 s. The depolarizations elicited
similar exocytotic responses from the TCF7L2-depleted
and control cells with fusion dynamics strongly depending
on the stimulation duration (Fig. 7) and Ca
2 current being
essentially identical in the two groups. The initial cell
capacitance of the TCF7L2-depleted cells was slightly
higher than that of control (11.4  0.7 pF versus 8.94  0.5
pF, P 	 0.05) and the exocytotic response to the mem-
brane depolarization was signiﬁcantly reduced in the
TCF7L2-depleted cells as compared with the control (Fig.
7A) for all pulse durations with the extent of the inhibition
decreasing from 
80% (0.2 s) to 
40% (2.5 s).
TCF7L2 shRNA and quantiﬁcation of granule number at the cell surface was as described in RESEARCH DESIGN AND METHODS. Images shown are
averages of 1-s movies acquired at 50 Hz and 20-ms exposure at 100 nm/pixel. Data are means  SEM, n  3 (30–35 cells per condition) (C). Scale
bar  2 m. Example graphs (D) of granule movement analysis from a representative control cell at different times and representative tracks (E)
of the different categories of granule movement observed after the addition of 30 mmol/l glucose. All tracks are 30 s or longer (1  beginning of
track, 2  end), and comparison (F) of the proportion of moving granules in TCF7L2 silenced and control -cells before and during application
of high glucose (n  5; 15–25 separate cells per condition; , scrambled; f, TCF7L2 shRNA). (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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The principal aims of this study were to determine the
impact of altering the level of expression of TCF7L2 on
glucose sensing and insulin secretion in pancreatic
-cells and to explore the underlying molecular mecha-
nisms. In addition to describing changes in the expres-
sion of genes involved in -cell survival and
proliferation (pin1, Ki67, and so on) consistent with
earlier ﬁndings (23,37), we demonstrate that several
genes involved in -cell function, that is, hormone
production and secretion, are also under the control of
TCF7L2.
FIG. 6. TCF7L2 expression does not affect the morphologically docked granule pool. A: Mouse islets were transfected with siRNA as described.
The total number of granules, morphologically docked, and within 200 nm of the membrane pools were analyzed as described in RESEARCH DESIGN
AND METHODS; n  14–16 cells per condition. B and C: Representative -cells with examples of docked granules and mitochondria (scrambled siRNA
[B] and TCF7L2 siRNA [C]). Scale bars  2 m.
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uration. It has previously been suggested that TCF7L2
may regulate the promoters for prohormone convertase-1
and -2 (17) and hence exert an effect on proinsulin
processing. The expression of neither gene was altered by
manipulating TCF7L2 levels in mouse islets (Fig. 4). Mouse
islets overexpressing TCF7L2 displayed higher slc30a8
(another gene associated with type 2 diabetes, which plays
a role in insulin processing) (9,39) gene expression (Fig.
4), whereas mouse islets in which TCF7L2 had been
silenced displayed decreased slc30a8 mRNA levels. How-
ever, although preproinsulin gene expression was reduced
(Fig. 4), no differences in granule number (Fig. 6), insulin
content, or insulin processing (supplemental Fig. 1, avail-
able in the online appendix) were observed after treat-
ment with TCF7L2 siRNA, suggesting that the acute effects
of TCF7L2 depletion on insulin secretion are not the result
of changes in insulin production.
TCF7L2 regulation of -cell survival. TCF7L2 knock-
down reduced expression of pin1 and ki67, a marker of
-cell proliferation (23). However, electron microscopy
analysis of -cells revealed no apparent change in
cellular ultrastructure indicative of endoplasmic reticu-
lum stress, mitochondrial damage, or nuclear conden-
sation. The observed inhibition of glucose-mediated
insulin secretion seems unlikely to be the result of
decreased cell viability.
Control by TCF7L2 of insulin synthesis and release.
The present study shows that reducing TCF7L2 expression
in the short term (48 h) affects the normal function of the
-cell, leading to a decrease in glucose-stimulated insulin
secretion (Fig. 1A–C). These changes were not associated
with major perturbations in the expression of genes en-
coding the glucose transporter GLUT2 or glucokinase (Fig.
4). Correspondingly, glucose-stimulated increases in cyto-
solic-free [Ca
2] and cellular adenine nucleotide concen-
tration (Fig. 2) were slightly enhanced on TCF7L2
depletion and no changes in the content of -cell calcium
channel subunits, sodium/calcium exchangers, PMCA, or
the calcium sensing synaptotagmins were observed (sup-
plemental Table 1, available in theonline appendix). Volt-
age-gated Ca
2 currents were unaltered (Fig. 7B), showing
that the channel capacity was unaffected.
These observations led us to postulate that the secretory
deﬁciency may be the result of defects at a late step in the
exocytotic process. Consistent with this view, real-time
PCR and immunoblot analysis of mouse islets treated with
TCF7L2 siRNA revealed increases in syntaxin 1A but
decreases in Munc18-1, mRNA, and protein levels (Figs. 4
and 5A–B). Fourfold overexpression of TCF7L2 increased
Munc18-1 and rab3a mRNA levels but did not alter syn-
taxin 1A expression or insulin secretion in islets, suggest-
ing syntaxin as the important effector of TCF7L2 effects. It
has been suggested that TCF7L2 can act as a transcrip-
tional repressor (40). Our overexpression data do not
suggest such a function for this clone.
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FIG. 7. TCF7L2 depletion affects membrane capacitance or voltage-
gated Ca
2 currents. Changes in -cell membrane capacitance (Cm)i n
response to a train of 10 pulses of 200-, 500-, or 2,500-msec depolar-
izations from 70 mV to 0 mV (n  16, scrambled; n  18, TCF7L2). A:
Absolute change in membrane capacitance. The number of data points
shown is reduced compared with those acquired by 200 for clarity. To
ﬁlter the data, a threshold for capacitance (7 pF bottom,1 3p Ftop) was
set considering the smaller/larger cells outliers. The pipette solution
contained (mmol/l): 125 Cs-glutamate, 10 NaCl, 10 CsCl, 1 MgCl2,3
MgATP, 0.1 cAMP, 5 HEPES (pH 7.15 with CsOH). The extracellular
(bath) solution contained (mmol/l): 118 NaCl, 20 TEA-Cl, 5.6 KCl, 5
glucose, 2.6 CaCl2, 1.2 MgCl2, 5 HEPES (pH 7.4 with NaOH). B:
Voltage-gated Ca
2 currents (n  22, scrambled; n  27, TCF7L2). f,
TCF7L2 siRNA; , scrambled siRNA.
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secretion. Transgenic mice overexpressing syntaxin 1A
exhibit insulin secretory defects and reduced Ca
2 cur-
rents (41). We did not observe evidence for any corre-
sponding changes in free [Ca
2]i in mouse islets treated
with siRNA for TCF7L2 (Fig. 2A), suggesting that the
inﬂuence of augmented syntaxin 1A expression on insulin
release events is likely to be exerted through an alteration
on the fusion potential of the granules in response to a
glucose challenge.
Munc18-1 is an important modulator of the folded
conformation of syntaxin 1A, and decreased Munc18-1
expression has been seen in islets from patients with type
2 diabetes (42) and GK rats (43). In PC12 cells, increased
syntaxin 1A and decreased Munc18-1 levels had a negative
effect on membrane trafﬁcking and catecholamine secre-
tion (44). TCF7L2 consensus binding sites (WWCAAWG)
were identiﬁed in the 5
 untranslated region of both the
human and mouse syntaxin 1A and Munc18–1 (using
TFExplorer [http://tfexplorer.org]), suggesting that they
may be direct targets for regulation by TCF7L2 (supple-
mental Fig. 2, available in the online appendix). The
increase in syntaxin 1A and decrease in Munc18–1 levels
described here may account, at least in part, for the
defective glucose-stimulated insulin secretion observed in
TCF7L2-depleted cells.
Despite a strong reduction in insulin secretion, we did
not observe any clear alteration in the number of near-
plasma membrane granules in TCF7L2 siRNA-treated is-
lets by TIRF (Fig. 5C) or electron microscopy (Fig. 6A).
There were no observable alterations in the expression of
trafﬁcking proteins Myosin5a or Kif5b (Fig. 4) or in the
actin network structure (supplemental Fig. 4, available in
the online appendix), suggesting that granule targeting to
the cell surface is unaffected. Under conditions in which a
repeated mild stimulation was applied (Fig. 7B)t om i m i c
the effects of glucose on [Ca
2]i, -cells silenced for
TCF7L2 showed impaired capacitance increases. The in-
hibitory effects of TCF7L2 deletion were substantially
more marked at shorter pulse durations (0.2 s), most
closely mimicking the spontaneous action potentials nor-
mally triggering insulin exocytosis in response to glucose
than at longer pulse durations (0.5 or 2.5 s), approaching
the effects of sustained depolarization with KCl (Fig. 7A).
Coupled with the increase in granule movements seen in
the later stages of glucose stimulation by TIRF microscopy
(Fig. 5E and F), this observation suggests that the selective
inhibition of glucose- but not KCl-stimulated insulin secre-
tion may reﬂect the combined effect of failure to recruit
competent granules and defective vesicle fusion during
repetitive [Ca
2]i increases.
The present studies demonstrate that near complete
ablation of TCF7L2 is likely to have marked effects on
insulin release from pancreatic -cells. It should be em-
phasized, however, that the extent of these changes is
likely to considerably exceed those observed in carriers of
the at-risk T-allele of TCF7L2. Future studies will be
required to assess how more subtle variations in TCF7L2
level impact on -cell function and survival.
In conclusion, lack of functional TCF7L2 leads to defec-
tive glucose-stimulated insulin secretion. This is probably
attributable, in part, to changes in the expression of key
regulatory genes and processes involved in granule re-
cruitment and exocytosis.
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